Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.2% Today

What is Tandem Diabetes Care, Inc.?

Tandem Diabetes Care Inc. is a leading medical device company specializing in innovative solutions for diabetes management. Today, the stock TNDM experienced a strong bearish movement in the market.

Why is Tandem Diabetes Care, Inc. going down?

TNDM stock is down 5.2% on Mar 6, 2026 16:01

• The expansion of Tandem's Mobi automated insulin delivery system to Android smartphones, while a positive development for accessibility and user convenience, may have raised concerns about potential competition in the market, leading to a bearish sentiment among investors.
• Despite receiving rating upgrades and achieving over $1 billion in worldwide sales, the market may have reacted negatively to the stock due to profit-taking by investors who were anticipating a bullish run following these positive developments.
• The announcement of further innovations planned for 2026, including a tubeless Mobi pump and an advanced insulin algorithm, could have created uncertainty among investors about the company's ability to maintain its current growth trajectory, contributing to the bearish movement in the stock price.

TNDM Price Chart

TNDM Technical Analysis

TNDM News

Tandem Diabetes expands Mobi Insulin Pump to Android users

Tandem Diabetes Care Inc. has expanded its Mobi automated insulin delivery system to include compatibility with Android smartphones, making it accessible to a wider range of users beyond the initial iPhone-only launch. The FDA-cleared technology, powered by Control-IQ+, is available on select Google Pixel and Samsung Galaxy models, offering users improved time-in-range for glucose levels and a compact, discreet pump design. This move reflects a broader industry trend toward smartphone-controlled, miniaturized, and highly effective automated insulin delivery systems.

https://www.medicaleconomics.com/view/tandem-diabetes-expands-mobi-insulin-pump-to-android-users

Tandem Mobi Now Compatible with Android Smartphones

Tandem Diabetes Care, Inc. has announced that its Tandem Mobi insulin delivery system is now compatible with Android smartphones in the U.S. This expansion allows more users to manage their diabetes directly from their personal devices, enhancing convenience and flexibility. The Mobi system, powered by Control-IQ technology, aims to broaden access to advanced diabetes management for a wider population.

https://www.eagletribune.com/region/tandem-mobi-now-compatible-with-android-smartphones/article_fde49c25-203d-5006-abf0-285d45536079.html

Tandem Mobi Now Compatible with Android Smartphones

Tandem Diabetes Care has announced that its Tandem Mobi automated insulin delivery system is now compatible with Android smartphones in the U.S. This expansion allows more users to manage their diabetes directly from their Android devices, following its initial launch with iPhones in 2024. The system, recognized for its small size and driven by Control-IQ+ technology, aims to enhance convenience and accessibility for individuals with diabetes.

https://www.businesswire.com/news/home/20260304073769/en/Tandem-Mobi-Now-Compatible-with-Android-Smartphones

Tandem Diabetes Care Receives Analyst Rating Upgrades

Tandem Diabetes Care, a San Diego-based medical device company, has recently received several rating upgrades and price target changes from industry analysts. The positive sentiment is primarily due to the company's innovative t:slim X2 Insulin Pump, which integrates continuous glucose monitoring and automated insulin delivery. This could boost investor confidence and increase product adoption, benefiting individuals with insulin-dependent diabetes.

https://nationaltoday.com/us/ca/san-diego/news/2026/03/02/tandem-diabetes-care-receives-analyst-rating-upgrades/

Tandem Bests $1B Worldwide Sales

Tandem Diabetes Care Inc. has achieved over $1 billion in worldwide sales for the first time, driven by strategic changes including modernizing its salesforce, improving market access with a pharmacy benefit model, and continued product innovation. The shift to a pay-as-you-go pharmacy model for its Mobi pump significantly boosted revenue and investor confidence, leading to a substantial increase in stock value and a $265 million private placement. The company plans further innovations in 2026, including a tubeless Mobi pump and an advanced insulin algorithm.

https://www.sdbj.com/life-sciences/medical-devices/tandem-bests-1b-worldwide-sales/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.1% Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.0% Today

Ambarella Inc. ($AMBA) Stock Forecast: Down 5.3% Today

Monolithic Power Systems Inc. ($MPWR) Stock Forecast: Down 5.3% Today

Fortune Brands Innovations Inc. ($FBIN) Stock Forecast: Down 5.2% Today

The Cooper Companies Inc. ($COO) Stock Forecast: Down 5.1% Today

Carnival Corporation ($CCL) Stock Forecast: Down 5.1% Today

Bruker Corporation ($BRKR) Stock Forecast: Down 5.1% Today

V.F. Corporation ($VFC) Stock Forecast: Down 5.0% Today

Revvity ($RVTY) Stock Forecast: Down 5.1% Today

Tandem Diabetes Care, Inc. Price History

24.01.2026 - TNDM Stock was up 5.3%

• Tandem Diabetes Care's bullish movement today could be attributed to the positive market reception of its proposed private placement of convertible notes, signaling investor confidence in the company's growth prospects.
• The upgrade of Tandem Diabetes Care's stock rating by Lake Street Capital Markets, driven by the successful transition to a pharmacy distribution model, likely contributed to the bullish sentiment surrounding the company.
• The projected significant growth of the global insulin delivery devices market, with insulin pumps expected to dominate the market share, could have also positively influenced Tandem Diabetes Care's stock performance as a key player in this industry.
• Overall, the combination of strategic financial moves, positive analyst outlook, and favorable market trends in the healthcare sector likely fueled Tandem Diabetes Care's strong bullish movement today.

20.01.2026 - TNDM Stock was up 31.3%

• Adjusting Tandem Diabetes Care's price target upwards and maintaining a Hold rating likely contributed to investor optimism and buying interest in the stock.
• Tandem Diabetes Care's record-setting Q4 and full-year 2025 financial performance, surpassing $1 billion in sales, and achieving double-digit growth with improved profitability, showcased the company's strong fundamentals and growth potential.
• The strategic shift towards a "pay-as-you-go" reimbursement structure in the U.S. pharmacy channel, despite near-term revenue headwinds, signals a long-term focus on market expansion and profitability, which could have positively influenced investor sentiment.
• The introduction of new technologies like Control-IQ+ and Mobi Tubeless, along with strong financial results and optimistic 2026 guidance, likely fueled investor confidence and contributed to the significant bullish movement in Tandem Diabetes Care's stock price.

23.01.2026 - TNDM Stock was up 10.1%

• Tandem Diabetes Care's stock witnessed a surge of over 32% due to record margins and a revenue beat, supported by strong demand for its insulin pumps and enhanced gross margin.
• An upgrade by Lake Street Capital Markets to a Buy rating with a price target of $50.00 bolstered investor confidence, underscoring the company's successful shift to a pharmacy distribution model.
• The projected growth of the global insulin delivery devices market, particularly in insulin pumps leading the market share, also contributed to positive sentiment surrounding Tandem Diabetes Care.
• A combination of robust financial performance, margin expansion, and positive sales forecasts for 2026 resulted in a short squeeze and a notable increase in Tandem Diabetes Care's stock price.

23.01.2026 - TNDM Stock was up 6.3%

• Tandem Diabetes Care (TNDM) saw a remarkable 33% surge in its stock performance today, propelled by exceptional margins and outperforming revenue figures, prompting a short squeeze and a notable price upswing.
• The company delivered robust results in the fourth quarter, driven by a strong demand for its insulin pumps and an enhanced gross margin, contributing to the significant rise in its stock value.
• With an innovative pay-as-you-go pharmacy model that is augmenting margin expansion and generating recurring revenue, Tandem Diabetes Care is well-positioned for sustained profitable growth in 2026, with anticipated sales ranging between $1.065 billion and $1.085 billion.
• Tandem Diabetes Care's strategic initiatives for future expansion, such as the emphasis on the "pay-as-you-go" approach and the projected increase in pump shipments for 2026, have elicited positive responses from investors and analysts, despite a slightly lower-than-expected sales forecast for the fiscal year 2026.

20.01.2026 - TNDM Stock was up 19.0%

• Tandem Diabetes Care outperformed revenue expectations in Q4 2025 with a 15% increase year-over-year and a GAAP EPS loss of $0.01, surpassing projections. This strong financial performance is believed to have fueled the stock's bullish movement.
• Despite providing cautious 2026 sales guidance due to challenges from new business models, investors are optimistic about the company's strategic repositioning and improved profitability forecasts for 2027 and beyond, resulting in an increase in the stock's value in after-hours trading.
• The company's robust Q4 results, which exceeded revenue and EPS forecasts, coupled with positive future profitability prospects, likely bolstered investor confidence and led to the stock's upward trajectory.
• Tandem Diabetes Care's ability to beat revenue expectations, enhance operating margin, and achieve over $1 billion in global sales for 2025 demonstrates its strength and growth potential, which probably attracted investors and contributed to the favorable market movement.

20.01.2026 - TNDM Stock was up 39.4%

• Following the release of its Q4 2025 earnings report, Tandem Diabetes Care (TNDM) saw a strong bullish movement, with record-setting sales surpassing $1 billion and double-digit growth.
• Positive market response was observed towards TNDM's enhanced profitability, operational improvements, and the launch of new technologies like Control-IQ+ and Mobi Tubeless, reflecting investor confidence in the company's strategic direction.
• Despite issuing cautious sales guidance for 2026 due to transitional challenges from new business models, investors displayed optimism in TNDM's potential long-term profitability, leading to a rise in the stock price during after-hours trading.
• TNDM's ability to surpass revenue projections, enhance operating margins, and anticipate ongoing sales growth, particularly with the introduction of new pay-as-you-go pharmacy structures, contributed to the optimistic sentiment surrounding the stock.

25.01.2026 - TNDM Stock was down 7.8%

• The disclosure of pricing and upsizing details of the private placement of convertible senior notes due in 2032 likely sparked investor worries about possible share dilution, contributing to the prevailing bearish sentiment.
• Despite the favorable development of a stock rating upgrade by Lake Street Capital Markets attributed to a successful transition to a pharmacy distribution model, the attention on the convertible notes offering appeared to overshadow the favorable shift in the company's business approach.
• Investors are possibly exercising caution regarding the company's intention to utilize the proceeds for potential acquisitions, raising uncertainties about future growth and profitability.
• Market response suggests that while the strategic shift's long-term advantages are acknowledged, immediate concerns regarding share dilution and capital deployment choices are exerting a negative influence on the stock's performance.

19.01.2026 - TNDM Stock was down 5.2%

• The recent decline in TNDM's stock is linked to the ongoing legal concerns and heightened scrutiny stemming from a shareholder lawsuit investigation concerning its t:slim X2 insulin pumps.
• Investor apprehension may be driven by the potential impact of this issue on the company's reputation, product reliability, patient confidence, and disclosure practices, potentially prompting a sell-off of the stock.
• While analysts had optimistic expectations for a narrower loss and increased revenue in the upcoming earnings announcement, uncertainties surrounding the legal inquiry and its financial consequences appear to have outweighed any positive projections, resulting in the downward trend in TNDM's market performance.

27.01.2026 - TNDM Stock was down 5.1%

• Reduction of stake by Envestnet Asset Management Inc. by 15% could have signaled lack of confidence in the company's future prospects, contributing to the bearish movement.
• Despite beating quarterly EPS and revenue estimates, the fact that Tandem Diabetes Care remains unprofitable might have raised concerns among investors, leading to the downward trend in the stock price.
• The pricing of an upsized private placement of convertible senior notes due 2032 could have diluted the value of existing shares, impacting the stock negatively.
• Mixed signals from analysts, with a "Hold" rating and a consensus target price of $28.00, might have added uncertainty to investors, influencing the bearish movement in the stock.

06.02.2026 - TNDM Stock was down 5.2%

• The expansion of Tandem's Mobi automated insulin delivery system to Android smartphones, while a positive development for accessibility and user convenience, may have raised concerns about potential competition in the market, leading to a bearish sentiment among investors.
• Despite receiving rating upgrades and achieving over $1 billion in worldwide sales, the market may have reacted negatively to the stock due to profit-taking by investors who were anticipating a bullish run following these positive developments.
• The announcement of further innovations planned for 2026, including a tubeless Mobi pump and an advanced insulin algorithm, could have created uncertainty among investors about the company's ability to maintain its current growth trajectory, contributing to the bearish movement in the stock price.

05.02.2026 - TNDM Stock was down 5.4%

• The introduction of Tandem Mobi's compatibility with Android smartphones, potentially broadening its user base, could have prompted concerns about technical issues or integration challenges, leading to uncertainty among investors and selling pressure on the stock.
• Despite receiving favorable analyst upgrades and surpassing $1 billion in worldwide sales, doubts voiced in the healthcare sector may have influenced market sentiment toward Tandem Diabetes Care, contributing to its recent stock decline.
• Anticipation surrounding the company's upcoming innovations in 2026, such as a tubeless Mobi pump and an enhanced insulin algorithm, may have raised expectations while also introducing uncertainty about execution and market reception, resulting in a negative impact on the stock price.
• When considering the expanded market reach, positive ratings, financial achievements, and industry doubts, the collective effect might have created varying investor sentiments, ultimately leading to the recent decline in TNDM stock value.

03.02.2026 - TNDM Stock was down 5.7%

• A decline in TNDM stock value is likely due to investors selling their shares to lock in profits following a period of positive updates and price increases.
• Despite achieving over $1 billion in worldwide sales and receiving analyst rating upgrades, concerns of future financial obligations arose when the company issued $300 million in zero-coupon convertible notes due 2032, potentially leading to stock pullback.
• Mixed financial results, including a reported net loss for the half-year and challenges related to a high debt-equity ratio, may have further fueled the negative investor sentiment surrounding TNDM stock.